NATHERA
Health Tech
The objective of this research is to develop a patch with nanotechnology that stimulates tissue regeneration in musculoskeletal conditions, improving the quality of life of patients.
Nanotherapy to improve well-being
Country:
Industry:
Status:
Valorization:
Chile
Health Tech
Early start-up
$20.000
TEAM
STATUS
Project Stage
Research phase
Patent Status
Patent not filed
FINANCING REQUIRED
$12.000
PROBLEM
Musculoskeletal conditions are the leading cause of disability globally. They significantly decrease and limit people’s mobility and dexterity, leading in many situations to early retirement of workers, a reduced ability to participate socially, and a low level of well-being. These conditions affect the muscles, bones, joints, tendons, ligaments and other structures related to the musculoskeletal system of the human body. Approximately 1.71 billion people worldwide live with musculoskeletal conditions, such as low back pain, neck pain, fractures, other injuries, osteoarthritis, amputation, and rheumatoid arthritis. Due to the sustained growth and aging of the population in recent years, this type of musculoskeletal conditions has increased rapidly.
SOLUTION
We are currently developing a nanoscaffold composed of PLGA filaments coated with collagen and other compounds that promote and favor tissue regeneration in this type of musculoskeletal conditions. Our nanometric-sized filaments constantly release collagen and other growth factors into the environment that promote the migration and beneficial development of fibroblasts to increase the efficiency of the tissue regeneration process, and therefore, directly impact people’s well-being. who suffer or have suffered from these types of conditions.
IMPACT
Our development has a tremendous impact on the nearly 2 billion people who are affected by this type of musculoskeletal injuries and which daily limit and reduce their work, functional, and social capacity. In that sense, we hope that our development will have a direct impact on reducing recovery times for these types of injuries, and also on the number of people disabled by these types of conditions.
2023
Stage 1: Create Startup
Stage 2: In vivo study of nanofilaments in a tissue damage model.
2024
Stage 3: Develop and validate Nathera technology
Stage 4: Preparation of a commercial formulation of the nanofilament.
2025
Stage 5: Nathera Commercial and Proprietary Rights
MILESTONES AND INDICATORS
- In vivo study
- Commercial formulation
Incomplete section